The PCE Price Index year over year rose 2.6% in December, in line with forecasts and following an increase of 2.4% in ...
What data tells us about the disparities along racial lines for income, savings, and overall financial well-being.
Colgate-Palmolive Co. shares are down 3.8% in premarket trades despite the toothpaste and toothbrush giant reporting better-than-expected fourth-quarter profit and hitting a full-year revenue ...
Progress on inflation was "noticeably" slower last year than in 2023, and upside risks to higher price pressures remain, and therefore the U.S. central bank should adopt a cautious and gradual ...
Fed Chairman Jerome Powell said earlier this week he expects inflation to turn lower again, but he did not say when he expected it to happen. The most recent Fed forecast shows PCE inflation ending ...
AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to ...
Barkley had such a dominant season that only the Buffalo Bills' Josh Allen and the Baltimore Ravens' Lamar Jackson - both star quarterbacks - have better odds than Barkley of winning the NFL MVP award ...
The holiday shopping season was a gift of sorts to the economy: Consumer spending surged in December to cap off another strong year of growth and position the U.S. to expand briskly again in early ...
The employment cost index increased 0.9% from October to December, the government said Friday. That's up slightly from an 0.8% gain in the prior quarter, which was the slowest increase in three years.
Southwest Airlines Co. may be at risk of a comment letter from the Securities and Exchange Commission after including adjusted revenue in its fourth-quarter earnings report published early Thursday.
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025.